Piramal Pharma Limited (PPLPHARMA) Fair Value & Analysis
Healthcare · IN · Market cap ₹234B
Fair value as of: Jul 3, 2026
From 15 valuation models · updated today
Share price +5.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹133.27 – ₹216.88 · fair‑value band ₹39.39 – ₹88.01 · the ₹175.95 price screens above the ₹63.70 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Piramal Pharma Limited (PPLPHARMA) currently trades at ₹175.95, while our model-based Fair Value estimate is ₹63.70 — implying the stock looks roughly 63.8% overvalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Piramal Pharma Limited generated revenue of ₹88.7B at a net margin of -3.7%. Revenue declined 0.1% year over year. It earns a return on equity of -4.0%. Net debt stands at ₹44.5B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Piramal Pharma Limited reported revenue of ₹88.7B in FY2026 versus ₹64.7B in FY2022, a compound +8.2%/yr. Reported net income was −₹3.3B in FY2026.
Is PPLPHARMA fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Piramal Pharma Limited (PPLPHARMA) undervalued?
What is the fair value of PPLPHARMA?
What is the quality score of PPLPHARMA?
What is the revenue of Piramal Pharma Limited (PPLPHARMA)?
What is the net profit margin of PPLPHARMA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.